AIM
APLS

Aigen Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Aigen Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,181
Closed -$321K – 578
2025
Q3 		$321K Buy
+14,181
New +$331K 0.05% 518
2025
Q2 		– Sell
-15,621
Closed -$342K – 778
2025
Q1 		$342K Buy
+15,621
New +$432K 0.05% 459
2024
Q2 		– Sell
-5,560
Closed -$327K – 761
2024
Q1 		$327K Buy
+5,560
New +$354K 0.07% 404
2023
Q3 		– Sell
-21,827
Closed -$1.99M – 813
2023
Q2 		$1.99M Buy
+21,827
New +$1.88M 0.29% 90
2022
Q4 		– Sell
-3,438
Closed -$235K – 524
2022
Q3 		$235K Buy
+3,438
New +$203K 0.03% 474
2021
Q3 		– Sell
-5,097
Closed -$322K – 464
2021
Q2 		$322K Buy
+5,097
New +$263K 0.06% 318
2020
Q4 		– Sell
-10,308
Closed -$311K – 775
2020
Q3 		$311K Buy
+10,308
New +$308K 0.04% 528
2020
Q2 		– Sell
-29,412
Closed -$788K – 810
2020
Q1 		$788K Buy
+29,412
New +$1.04M 0.1% 281

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Aigen Investment Management's APLS Position: Q4 2025 in Review

Aigen Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 14,181 shares — an estimated $321K sold.

Aigen Investment Management first reported a position in APLS in Q1 2020 and held it in 8 quarters. The position peaked at $1.99M in Q2 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Aigen Investment Management reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Aigen Investment Management sold 14,181 Apellis Pharmaceuticals shares in Q4 2025, an estimated $321K.
  • Aigen Investment Management first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • Aigen Investment Management's Apellis Pharmaceuticals position peaked at $1.99M in Q2 2023.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Aigen Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.